close

Enter

Log in using OpenID

Recombinant Therapeutic Antibodies and Proteins Market Growth Outlook to 2026

embed
The global recombinant therapeutic antibodies and proteins market size was valued at US$ 91.2 billion in 2017, and is expected to witness a robust CAGR of 12.2% By 2026
Recombinant Therapeutic Antibodies and Proteins
Market Size, Share, Trend, Outlook, Future
Growth Analysis And Synthesis 2018 - 2026
Therapeutic proteins are engineered in the laboratory for pharmaceutical use, including non-covalent
binders. These proteins are highly effective and serve as modernized treatment for rare as well as
chronic diseases. Protein therapeutics offer custom-made treatment approach by supporting a specifically
targeted therapeutic process by compensating the deficiency of an essential protein. Recombinant
proteins have gained significant traction for therapeutic applications and the number of proteins either
launched or approved into clinical trials has continually increased over the past two decades. According
to the National Center for Biotechnology Information (NCBI) data of 2017, the U.S. Food and Drug
Administration (FDA) approved over 140 recombinant therapeutic proteins for human use and several
hundred are currently in development. Majority of these proteins are recombinant monoclonal antibodies.
Free Request Sample of Report: https://www.coherentmarketinsights.com/insight/request-sample/1981
The global recombinant therapeutic antibodies and proteins market size was valued at US$ 91.2 billion
in 2017, and is expected to witness a robust CAGR of 12.2% over the forecast period (2018 – 2026).
Integration of novel approaches and strategies to modify protein drug products is an important aspect.
Advancements in recombinant protein technologies have allowed drug manufacturers and developers to
adjust required functional characteristics of proteins of interest while maintaining product efficacy and
safety.
Various recombinant technologies are currently in use to increase the half-life, functionality, and
targeting of novel therapeutic protein drugs and increase product purity and volume. For instance,
protein conjugation and derivatization methods, including albumin-fusion15, PEGylation and Fc-fusion
are currently being used to extend a drug’s circulating half-life.
Increasing government support for novel drug development is expected to augment the market growth
Governments are supporting research and development of novel products due to rapid advancements in
biomedical science and technology to address unmet medical needs. In 2012, the Food and Drug
Administration Safety and Innovation Act (FDASIA) was signed to provide the FDA with the capability to
establish breakthrough therapy designation (BTD), a new program within the Expedited Programs for
Serious Conditions. It was designed to be available for drugs designed to treat a serious condition and
that have been shown to exhibit initial clinical evidence of significant improvement over existing
treatments.
Report includes chapters which deeply display the following deliverable about industry :
• Recombinant Therapeutic Antibodies and Proteins Market Research Objective and Assumption
• Recombinant Therapeutic Antibodies and Proteins Market Purview - Report Description,
Executive Summary, and Coherent Opportunity Map (COM)
• Recombinant Therapeutic Antibodies and Proteins Market Dynamics, Regulations, and Trends
Analysis - Market Dynamics, Regulatory Scenario, Industry Trend, Merger and Acquisitions, New
system Launch/Approvals, Value Chain Analysis, Porter’s Analysis, and PEST Analysis
• Global Recombinant Therapeutic Antibodies and Proteins Market, By Regions
• Recombinant Therapeutic Antibodies and Proteins Market Competition by Manufacturers
including Production, Share, Revenue, Average Price, Manufacturing Base Distribution, Sales
Area and Product Type.
• Recombinant Therapeutic Antibodies and Proteins Market Manufacturers Profiles/Analysis
including Company Basic Information, Manufacturing Base and Its Competitors.
• Recombinant Therapeutic Antibodies and Proteins Market Manufacturing Cost Analysis
including Key Raw Materials and Key Suppliers of Raw Materials.
• Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials
Sourcing and Downstream Buyers
• Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market
Positioning and Distributors/Traders List.
• Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer
Preference Change and Economic/Political Environmental Change.
• Recombinant Therapeutic Antibodies and Proteins Market Forecast including Production,
Consumption, Import and Export Forecast by Type, Applications and Region.
• Research Findings and Conclusion
Competitive Landscape
Major players operating in the global recombinant therapeutic antibodies and proteins market include
Abbott, Amgen Inc., Biogen Inc., Eli Lilly and Company, F. Hoffmann-La Roche, Johnson and Johnson,
Merck & Co., Novo Nordisk, Pfizer Inc., and Sanofi S.A.
Detailed Segmentation:
Global Recombinant Therapeutic Antibodies and Proteins Market, By Drug Class:
•
Plasma Protein
•
Growth Factors
•
Fusion Proteins
•
Monoclonal Antibodies
•
Hormones
•
Enzyme
•
Coagulation Factors
•
Others
Global Recombinant Therapeutic Antibodies and Proteins Market, By Application:
•
Oncology
•
Hematology
•
Immunology
•
Endocrinology
•
Infectious Disease
•
Cardiovascular Diseases
•
Others
Find the comprehensive research report here with a single click:
https://www.coherentmarketinsights.com/market-insight/recombinant-therapeutic-antibodies-andproteins-market-1981
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering actionready syndicated research reports, custom market analysis, consulting services, and competitive
analysis through various recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]
Author
Poul Master
Poul Master247   documents Email
Document
Category
Uncategorized
Views
2
File Size
120 KB
Tags
recombinant, Recombinant Therapeutic Antibodies and Proteins Market
1/--pages
Report inappropriate content